相关实验视频

Updated: Jun 8, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

宫癌患者不同组织学亚型之间的生存比较:回顾性和倾向性得分匹配分析

Yugu Zhang^1,2, Pei Shu^1,2,3, Xin Wang^1,2

¹Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, People's Republic of China.

Journal of Cancer

|November 8, 2024

概括

与状细胞癌 (SCC) 相比,宫癌中的腺癌 (AC) 组织学与预后不佳和更高的远程复发风险有关. 腺状癌 (ASC) 的结果与SCC相似,这表明AC需要不同的治疗策略.

科学领域:

妇科瘤学妇科瘤学
癌症组织病理学癌症组织病理学
临床预后临床预后

背景情况:

宫癌表现出不同的组织学亚型,包括状细胞癌 (SCC),腺癌 (AC) 和腺状癌 (ASC).
这些亚型之间的预后差异,特别是经过标准手术和放射治疗后的预后差异,尚未完全阐明.

研究的目的:

研究宫癌组织学亚型 (ASC,AC,SCC) 与患者预后之间的相关性.
为了比较生存结果 (总生存率和无病生存率) 和不同组织学亚型的复发模式.

主要方法:

在2009-2018年期间接受治疗的714名宫癌患者的回顾性队列分析.
倾向性得分匹配 (1:3比) 用于平衡ASC/AC组与SCC.
评估5年总生存期 (OS),5年无病生存期 (DFS) 和复发模式 (局部与远程转移).

主要成果:

腺癌 (AC) 组织学与相匹配的SCC (95.2%的OS,92.8%的DFS) 相比,与显著较低的5年OS (82.1%) 和DFS (79.2%) 相关.
与SCC (8.7%) 相比,AC患者的远程复发率 (12%) 较高.
腺性瘤 (ASC) 显示了与匹配的SCC (93.4%的OS,81.2%的DFS) 的可比的5年OS (96.3%) 和DFS (92.6%),没有显著差异.

结论:

宫腺癌 (AC) 组织学表明预后不佳,患有远期复发风险较高.
腺状癌 (ASC) 的预后与状细胞癌 (SCC) 的预后类似.
由于其预后不佳,应探索超出传统治疗的替代治疗策略.

关键词:

腺癌瘤是一种腺癌.状腺癌 (Adenosquamous Carcinoma) 是一种状腺癌.宫癌:子宫癌是一种癌症.组织学类型组织学类型预后预后预后倾向性得分匹配的比分匹配状细胞癌的癌症.

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

相关概念视频

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...